Skip to content
OpenCapital
Get started

Vanda Pharmaceuticals VNDA Q1 2026 earnings

Reported May 6, 2026 · After market close

Revenue$51.7MMiss by $3.3M
EPS-$0.82Miss by $0.29
Revenue estimate$55.0M
EPS estimate-$0.53

Next report

Jul 30, 2026 (Tomorrow)
Revenue estimate$61.9M
EPS estimate-$0.58

Versus estimates

Revenue

Q1 2026$51.7MMiss by $3.3M
Q4 2025$57.2MMiss by $2.1MQ3 2025$56.3MMiss by $3.0MQ2 2025$52.6MMiss by $6.1MQ1 2025$50.0MBeat by $4.9MQ4 2024$53.2MBeat by $935.0K

Diluted EPS

Q1 2026-$0.82Miss by $0.29
Q4 2025-$0.46Beat by $1.72Q3 2025-$0.38Miss by $0.07Q2 2025-$0.46Miss by $0.12Q1 2025-$0.50Beat by $0.05Q4 2024-$0.08Beat by $0.06

Ask the moment Vanda Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Vanda Pharmaceuticals report Q1 2026 earnings?
Vanda Pharmaceuticals (VNDA) reported Q1 2026 earnings on May 6, 2026 after market close.
What were Vanda Pharmaceuticals's Q1 2026 revenue and EPS?
Vanda Pharmaceuticals reported revenue of $51.7M and eps of $-0.82 for Q1 2026.
Did Vanda Pharmaceuticals beat estimates in Q1 2026?
Revenue missed the consensus estimate of $55.0M by $3.3M. EPS missed the consensus estimate of $-0.53 by $0.29.
How did Vanda Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3.4% from $50.0M a year earlier and eps declined 64.0% from $-0.50.
Where can I find Vanda Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-031241) and the 10-Q periodic report (0001628280-26-031667) directly on SEC EDGAR. The filing index links above go to sec.gov.